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Pharmacokinetics of Cl-inhibitor protein in 
patients with acute myocardial infarction 
Objectives: Cl-inhibitor protein (Cl-INH) purified from pooled human plasma is used for the treatment of 
patients with hereditary angioedema. Recently, the beneficial effects of high-dose Cl-INH treatment on 
myocardial ischemia or reperfusion injury have been reported in various animal models and in humans. We 
investigated the pharmacokinetic behavior of Cl-INH in patients with acute myocardial infarction to calcu-
late the amount ofCI-INH required for optimal efficacy. 
Methods: Twenty-two patients received an intravenous loading dose, followed by 48 hours of continuous 
infusion of Cl-INH. Changes in the endogenous production of Cl-INH were evaluated in 16 control 
patients with acute myocardial infarction. A 2-compartment model was used to estimate the fractional 
catabolic rate constant (FCR), transcapillary escape rate constant (TER), and extravascular return rate 
constant (ERR) of Cl -INH. Software designed to analyze and fit measured data to unknown parameters in 
a system of differential equations was used to fit the experimental data against the 3-parameter model. 
Results:Withf'1Xed TERand ERR values (0.014 h- 1 and0.018 h- 1 , respectively), 20 of the 22 cases yielded 
well-determined FCR values, and simultaneous fitting resulted in a median FCR of 0.011 h- 1 (95% confi-
dence interval, 0.010 to 0.012 h- 1 ) versus 0.025 h- 1 as reported in healthy control patients. Simultaneous 
estimation ofTER, ERR, and FCR demonstrated weakly defined TER and ERR values, whereas the median 
FCR value remained unchanged. The use of a 2-compartment model resulted in a significantly better fit 
compared with the I -compartment model. Physiologic explanations are offered for discrepancies in the 
literature. 
Conclusions: Dose calculation of Cl-INH in patients treated with massive doses of Cl-INH requires turnover 
parameters that differ from those found in healthy subjects, possibly because of suppression of continuous 
Cl-INH consumption by target proteases. (Clin Phannacol Ther 2002;72:498-504.) 
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Cl-inhibitor protein (Cl-INH), a protein of approx-
imately 104 kd, regulates the classical activation path-
way of the complement system. 1 Patients with heredi-
tary angioedema (HAE), in whom there is a congenital 
lack of Cl-INH, have attacks of uncontrolled comple-
ment activation that may lead to life-threatening laryn-
geal obstruction or swelling of the gastrointestinal mu-
cosa.2 Depending on the severity of the edematous 
attack, treatment of patients with HAE usually consists 
of one or more bolus injections of CI-INH purified 
from pooled human plasma. 
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Other diseases in which complement inhibition 
might have beneficial effects are being explored, and 
the administration of Cl-INH has been investigated in 
patients with sepsis, 1 rheumatoid arthritis,3 and B-cell 
lymphoproliferative disorders.4 Recent studies in vari-
ous animal models have shown reduction of myocardial 
ischemia or reperfusion injury after high-dose Cl-INH 
therapy.5"8 To investigate the effects of Cl-INH in 
patients with acute myocardial infarction, we recently 
performed a dose-escalating pilot study.9 Patients were 
given an initial loading dose of Cl-INH, followed by 
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continuous infusion during the next 48 hours. Comple-
ment inhibition in this study proved to be strongly 
dose-dependent and necessitated accurate Cl-INH dos-
age control. However, Cl-INH was apparently elimi-
nated more slowly than expected from available data of 
patients with HAE. Therefore we decided to study the 
pharmacokinetics of Cl-INH in patients with acute 
myocardial infarction receiving high doses of this in-
hibitor. 
METHODS 
Twenty-two patients (12 men and 10 women; median 
age, 60.5 years) with acute myocardial infarction were 
admitted to the Intensive Coronary Care Unit, Univer-
sity Hospital Maastricht, The Netherlands. After in-
formed consent was obtained for patients to participate 
in an open-label pilot study, treatment with Cl-INH 
was started 6 hours after the onset of symptoms by 
means of 3 different dosage schemes as follows: an 
initial loading dose of 50 U/k:g body weight, followed 
by a continuous infusion of 1.25 U • kg- 1 • h- 1; an 
initial loading dose of 100 U/kg body weight, followed 
by a continuous infusion of 1.25 U • kg - l • h - l; or an 
initial loading dose of 100 U/kg body weight, followed 
by a continuous infusion of 2.00 U • kg - l • h - I during 
the next 48 hours. Loading doses were infused at a rate 
of 250 U/min. The administered amounts were chosen 
in an effort to reach concentrations between 200% and 
300% of normal. No presumptions were made about 
reaching steady-state conditions. Cl-INH (Cetor; CLB, 
Amsterdam, The Netherlands) was purified (>95%) 
from human plasma according to good manufacturer's 
practice guidelines and was tested for viral safety and 
clinical efficacy. The lyophilized protein was reconsti-
tuted in water before administration. 
Blood samples were collected before administration 
of the loading dose and at 1, 3, 6, 9, 12, 15, 18, 24, 36, 
48, and 72 to 96 hours after the start of loading dose 
administration. Clotting was prevented with ethyl-
enediaminetetraacetic acid (EDTA), and plasma sam-
ples obtained by immediate routine centrifugation were 
stored at -70°C until further analysis. 
Changes in endogenous Cl-INH production after 
acute myocardial infarction were assessed by measur-
ing the course of plasma C 1-INH in 16 control patients 
with acute myocardial infarction who did not receive 
Cl-INH. These patients were admitted to the Depart-
ment of Cardiology, VU University Medical Center, 
Amsterdam, The Netherlands. 10 Blood samples were 
collected at admission and at 2, 6, 12, 24, 36, 48, 60, 
and 72 hours thereafter. After centrifugation, plasma 
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Fig 1. Two-compartment model. QP(t), Amount of Cl inhib-
itor (Cl-INH) in plasma (in units) at time t; Q.,(t), amount of 
extravascular Cl-INH (in units) at time t; VP' plasma volume; 
Med(t), input function ofCl-INH; TER, transcapillary escape 
rate constant; ERR, extravascular return rate constant; FCR, 
fractional catabolic rate constant. 
was collected and stored in aliquots at - 70°C until 
assays were performed. 
C 1-INH concentrations were determined with the use 
of a commercially available functional assay based on 
a chromogenic assay (Berichrom Cl inhibitor assay; 
Behringwerke AG, Marburg, Germany). Values were 
expressed in units per liter, with 1 unit equal to the 
activity of Cl-INH in 1 mL of pooled plasma obtained 
from healthy donors. The specific activity of Cl-INH 
was 3.8 U/mg protein. 
A 2-compartment model, as described in Fig 1, was 
used to estimate individual pharmacokinetic parameters 
of Cl-INH. Time-related changes in plasma and ex-
travascular Cl-INH pools are given by the following 
equations: 
dQp(t)/dt = MED(t) - (FCR + TER) X Qp(t) (la) 
+ERR x Q.(t) 
dQ.(t)/dt = TER x Qp(t) - ERR X Q0(t) (lb) 
in which QP(t) and Qe(t) are the plasma and extravas-
cular pools, respectively, expressed in units at time t, 
MED(t) is the input function of Cl-INH, FCR is the 
fractional catabolic rate constant (per hour) for the 
elimination of Cl-INH from the plasma, TER is the 
transcapillary escape rate constant (per hour) of Cl-
INH for extravasation of Cl-INH to the extravascular 
compartment, and ERR is the extravascular return rate 
constant (per hour) for the return of Cl-INH from the 
extravascular compartment to plasma. 
Equation 2, used as an initial condition, presents 
steady-state conditions for the amount of C 1-INH in the 
extravascular compartment at time 0. Qp(O) is known 
500 Diris et al 
3.50 
3.00 
§ 
~ 2.50 
0 
~ ~ 2.00 
~ 
c: 8 1.50 
:::c 
z 
... 1.00 
CLINICAL PHARMACOLOGY & THERAPEUTICS 
NOVEMBER 2002 
0 C1 -INH administration 
0.50 
o.oo+-~~~~~~~~~.....-~~--..~~~~~~~~ 
0 12 24 36 48 60 72 
Time after the onset of symptoms (h) 
Fig 2. Cl-INH plasma curves of 3 infusion groups and control patients (mean with standard error). 
Group I (squares): Loading dose. 50 U/kg; infusion rate, l.25 U • kg- 1 • h- 1 (n = 6). Group 2 
(circles): Loading dose, 100 U/kg; infusion rate, 1.25 U • kg- 1 • h- 1 (n = 5). Group 3 (diamonds): 
Loading dose, 100 U/kg; infusion rate, 2.00 U • kg- 1 • h--t (n = 11). Control patients (triangles): 
No Cl-INH administered (n = 16). 
by measurement of the Cl-INH plasma concentration at 
time 0 (ie, before Cl-INH administration). 
Q.(O) = [TER/ERR] X Qp(O) (2) 
All plasma concentrations were converted to total 
amounts in units by multiplying the concentrations in 
units per liter by the individual plasma volume in liters. 
Plasma volume was calculated from the initial increase 
in Cl-INH concentration after administration of the 
loading dose. 
A software package called splds, 11 developed for 
estimation of unknown parameters in time-dependent 
dynamic systems, 12 was used to solve the system de-
fined by the differential algebraic equations la and lb 
and the initial condition given by equation 2. It uses the 
algebra package Maple V (Waterloo Maple Inc, On-
tario, Canada) to derive variational equations from the 
differential equations. These variational equations are 
then used in the process by combining them with the 
initial differential equations. The Levenberg-Marquardt 
method was used to minimize the total sum of squared 
discrepancies between calculated and measured values 
of QP. A confidence interval (Cl) at a user-defined level 
a (ie, .05) is calculated for each estimate. The program 
also gives a detailed analysis of the reliability and 
interdependencies of the parameters. This is used to 
evaluate whether each parameter independently con-
tributes to a significant decrease in the total sum of 
squares. Thus we can verify whether the use of a 
2-compartment model is to be preferred over a 
I -compartment model. 
RESULTS 
Fig 2 shows mean plasma C 1-INH concentrations for 
the 3 patient groups with different dosage schemes and 
for the control patients. A clear dose-concentration 
profile is visible in the 3 groups that received Cl-INH 
therapy. A decrease in Cl-INH is shown in the group of 
control patients in the first 6 hours after the onset of 
symptoms, and a slow but continuing increase in Cl-
INH concentration after 6 hours can be noted in the 
same group. 
Fig 3 demonstrates the mean observed and fitted 
Cl-INH plasma concentration curves, as well as the 
calculated extravascular Cl-INH pool, for each dosage 
group. After a rapid increase caused by the loading 
dose, a plateau phase is visible for the duration of the 
infusion. When the infusion was stopped, a gradual 
decline in the plasma concentration was seen, while the 
extravascular pool continued to increase, albeit with 
diminishing speed. The latter finding indicates that no 
steady-state conditions were reached. 
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Fig 3. Time course of Cl-INH plasma concentration and extravascular content after treatment 
(mean with standard error [n = 22]). Upper panel, Plasma concentrations (in units per milliliter) in 
group 1 (squares), group 2 (circles), and group 3 (diamonds). Solid lines, Measured Cl-INH plasma 
concentrations; dotted lines, fitted Cl-INH plasma concentrations. Lower panel, Calculated ex-
travascular Cl-INH pool (in units) in group 1 (squares), group 2 (circles), and group 3 (diamonds). 
On the basis of plausible fixed TER and ERR values 
(0.014 h- 1 and0.018 h- 1, respectively; see Discussion 
section), the FCR for individual patients was estimated. 
The results listed in Table I demonstrate that 20 of the 
22 cases had well-determined FCR values, with Cls of 
less than 55%. The 2 cases with Cls greater than 100% 
both underwent sampling for only a short period of time 
(<30 hours) because of difficulties with blood sam-
pling (not drug-related). Simultaneous fitting of the 
remaining 20 patients with fixed TER and ERR values 
yielded the same FCR as the calculated median (0.011 
h - l ), but this value was better defined (Table I). 
Estimation of all 3 parameters resulted in almost the 
same FCR value, 0.012 h- 1 (Cl, 0.002 to 0.022 h- 1). 
The TER and ERR values were 0.021 h- 1 (Cl, -0.018 
to 0.060 h- 1) and 0.019 h- 1 (Cl, -0.055 to 0.093 h- 1), 
respectively, but the large Cls indicate that no precise 
TER and ERR values could be determined. 
DISCUSSION 
Recovery of Cl-INH 
From the plasma volumes and individual body 
weights listed in Table I, a median plasma volume of 48 
mL/kg body weight was calculated. Comparison with 
the normal plasma value of 41 mL/kg (corrected for 
sex, weight, and age)13 showed an apparent incomplete 
recovery (85%) of Cl-INH, probably caused by con-
sumption of C 1-INH in the acute phase. This finding is 
supported by the initial decrease in Cl-INH in control 
patients (Fig 2). 
Validation of model used 
On the basis of the independency of the parameters 
(data not shown), adding a second compartment to the 
model caused a significant reduction in the total sum of 
squares. This means that, although the data obtained 
lack extravascular measurements, the use of a 
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Table I. Results of 2-compartment model on patients with acute myocardial infarction 
Patient no. Sex Age (y) Body weight (kg) VP (ml) FCR and 95% Cl (h-1)* 
1 F 74 75 2953 0.009 (0.005 to 0.013) 
2 M 51 107 5144 0.009 (0.008 to 0.010) 
3 M 60 85 4474 0.007 (0.005 to 0.009) 
4 M 58 105 4953 0.005 (0.003 to 0.007) 
St F 55 55 2500 0.900 (-0.470 to 2.270} 
6 F 38 71 3170 0.011 (0.010 to 0.012) 
7 M 61 88 3411 0.012 (0.009 to 0.015) 
8 F 46 60 2970 0.003 (0.002 to 0.004) 
9 F 70 56 2857 0.011 (0.008 to 0.014) 
10 M 57 75 5068 0.010 (0.005 to 0.015) 
11 M 40 78 3000 0.021 (0.017 to 0.025) 
12 M 51 80 4420 0.010 (0.006 to 0.014) 
13 M 63 70 3784 0.017 (0.012 to 0.022) 
14 F 83 64 2795 0.016 (0.014 to 0.018) 
15 F 78 73 3106 0.016 (0.011 to 0.021) 
16 M 59 70 3590 0.025 (0.021 to 0.029) 
17t F 74 58 2929 0.002 (-0.004 to 0.008) 
18 M 61 100 6329 0.017 (0.010 to 0.024) 
19 M 61 82 4059 0.007 (0.004 to 0.010) 
20 M 68 93 4769 0.009 (0.007 to 0.011) 
21 F 57 96 3254 0.012 (0.005 to 0.019) 
22 F 68 87 3750 0.011 (0.009 to 0.013) 
Median (n = 20) 60.5 77 3500 O.Oll (0.008 to 0.014) 
VP' Plasma volume; FCR, fractional catabolic rate constant; CI, confidence interval; F, female; M, male. 
*Simultaneous fit of 20 patients (fixed transcapillary escape rate constant [0.014 h-11 and extravascular return rate constant [0.018 h-1]): FCR = 0.011 h-1 (95% Cl, 
0.010 to 0.012 h-1). Individual fit of 20 patients (estimation of all 3 parameters): FCR = 0.012 h-1 (95% Cl, 0.002 to 0.022 h-1). 
tSampling period <30 hours; therefore patient's data were excluded from calculations. 
2-compartment model still results in a better fit of the 
plasma curves compared with a I-compartment model. 
TER and ERR values 
The choice of plausible fixed values for TER (0.014 
h- 1) and ERR (0.018 h- 1) in this study was based on 
an overview of data on the behavior of circulating 
proteins in humans. 14 These data, in most cases ob-
tained from turnover studies of radiolabeled proteins, 
show an average extravasation rate of about 1.4% of the 
plasma pool per hour for proteins with a molecular 
weight exceeding 100 kd. Moreover, it was found that 
the extravascular pool of such proteins is somewhat 
smaller than the plasma pool, as also follows from the 
equilibrium relation E/P = TERJERR = 0.78, where 
E/P is the extravascular pool/plasma pool ratio. 
The fact that no precise TER and ERR values for 
Cl-INH could be determined is mainly caused by the 
lack of extravascular measurements. The small number 
of observations (2 or 3) made after the end of infusion 
enlarges the imprecision of TER and ERR because it is 
primarily this last part of the plasma curve that ex-
presses these values. 
Estimation of FCR: Comparison with data from 
literature 
Table II presents an overview of Cl-INH turnover 
studies in healthy subjects and in patients with various 
diseases. Apart from this study, all studies used single 
intravenous bolus injections of Cl-INH. With the ex-
ception of the study of Kunschak et al, 15 in which the 
total observation time was limited to 24 hours, Cl-INH 
concentrations were measured for at least 72 hours. 
In a number of these studies15-17 the apparent disap-
pearance rate constant (kct) rather than the true frac-
tional catabolic rate constant for the disappearance of 
Cl-INH from plasma was determined. For instance, 
Brackertz et a116 found a biphasic disappearance of 
injected Cl-INH in control subjects and reported a 
plasma half-life of 64 hours for the final slow disap-
pearance phase from 3 to 8 days after injection. How-
ever, the corresponding apparent disappearance rate 
constant kd = (ln2)/64 = 0.011 h- 1 also incorporates 
the return of extravascular Cl-INH to plasma, which 
suggests that the FCR would be even lower than 0.011 
h-1. 
Another situation occurred in the study of Kunschak 
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Table II. Data from literature on human C 1 inhibitor turnover 
Cl-INH kd FCR TER ERR TER/ERR 
Reference Subjects preparation (h-1) (h-1) (h-1) (h-1) = EIP Method 
Brackertz et al16 Controls (n = 3) Iodine label 0.011 Exponential fit {kd from 
(1975) Hereditary angioedema 0.010 second phase) 
(n = 3) 
Quastel et al18 Controls (n = 9) Iodine label 0.025 0.60 Matthews (2-compartment 
(1983) Hereditary angioedema 0.035 1.26 model) or Nosslin (non-
{n = 5) compartmental model) 
Woo et al3 Controls (n = I 0) Iodine label 0.025 Matthews (2-compartment 
(1985) Rheumatoid arthritis 0.028 model) 
(n = 13) 
Melamed et al4 LPD (n = 5) Iodine label 0.053 1.54 Matthews (2-compartment 
(1986) model) 
Waytes et al17 Hereditary angioedema Concentrate 0.015 Half-life estimation over 
(1996) (n = 6) 72 h 
Kunschak et al15 Hereditary angioedema Concentrate 0.018 t112 activity 
(1998) (n = 10) 0.029 t112 antigen (kd first phase) 
This study Acute myocardial Concentrate 2-Compartment fit: 
infarction (n = 22) 0.011 0.014 0.018 0.78 TER, ERR (fixed) 
0.012 0.021 0.019 1.11 TER, ERR (free) 
0.015 Corrected for endogenous 
Cl-INH, Cl inhibitor; le,., apparent disappearance rate constant; TER, transcapillary escape rate constant; ERR, extravascular return rate constant; E/P, extravascular 
pool/plasma pool; LPD, lympboproliferative disorder; t 112, half-life. 
et al, 15 who reported half-lives of 37.8 to 24.0 hours for 
the initial disappearance phase of Cl-INH in patients 
with HAE, corresponding to kd values of 0.018 to 0.029 
h - 1• These values are indeed higher than the true FCR, 
because Cl-INH is not only catabolized but also ex-
travasating during the first 24 hours after a bolus injec-
tion. 
Overall, Table II shows that an FCR value of 0.025 
h - l was obtained in healthy subjects and that higher 
values are obtained in patients with various diseases 
that cause consumption of C 1-INH as a result of com-
plement activation, such as HAE, rheumatoid arthritis, 
and various forms of leukemia. 
Possible explanations for discrepancies in FCR 
values 
A first explanation for the relatively low FCR value 
could be a considerable increase in endogenous pro-
duction of Cl-INH in the days after acute myocardial 
infarction. Such acute phase reactant-like behavior of 
C 1-INH could compensate for the extra consumption of 
Cl-INH as a result of complement activation during the 
first 24 hours after acute myocardial infarction. How-
ever, the course of Cl-INH plasma levels in the control 
patients did not support this explanation, given that 
levels initially decreased rather than increased (Fig 2), 
suggesting increased consumption and not increased 
synthesis. 
Furthermore, increased endogenous production of 
acute phase reactants usually starts after more than 24 
hours, and Fig 2 indeed shows that Cl-INH plasma 
concentrations in control patients are increasing slightly 
in the days after acute myocardial infarction. On the 
basis of data from these patients, it was estimated that 
this slow increase corresponded to an average increase 
in Cl-INH synthesis of 17 U/h. When this production 
was added to equation la, it was found that the FCR 
changed only marginally to 0.015 h- 1 (Cl, 0.013 to 
0.017 h- 1) (Table II). 
Another explanation for the discrepancy between 
healthy subjects and patients with acute myocardial 
infarction could be that continuous consumption of 
Cl-INH caused by complex formation with activated 
proteases and subsequent rapid removal of complexes 
from plasma is a main determinant of Cl-INH elimi-
nation in healthy subjects. If it is assumed that the 
disappearance of functional Cl-INH proceeds via 2 
almost equally contributing pathways, (1) inactivation 
resulting from complex formation and (2) slow hepatic 
removal of Cl-INH with an FCR value of about 0.011 
h- 1, it is clear that in studies that used lower doses the 
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combination of 2 removal pathways could be mistaken 
for a higher FCR value. 
An obvious difference between the other studies 
mentioned in Table II and this study is that we used 
bulk amounts of Cl-INH instead of trace amounts of 
radiolabeled Cl-INH. Patients with HAE are usually 
treated with doses of 1000 U. In contrast, the patients 
with acute myocardial infarction in this study received 
total doses of as much as 20,000 U. At these high doses, 
disappearance as a result of complex formation will 
play only a relatively minor role, as compared with 
hepatic removal of functional C 1-INH. This could re-
veal the observed FCR value of 0.011 h - 1• 
A similar low FCR value was found by Quastel et 
al 18 for a dysfunctional Cl-INH protein, Ta. They 
reported that Cl-INH Ta scarcely binds to Cl. This too 
supports the idea of the important role of continuous 
Cl-INH disappearance from plasma as a result of com-
plex formation. The defective complex formation of Ta 
blocked one of the two pathways, thus decreasing the 
speed of disappearance and revealing the true FCR. 
In conclusion, pharmacokinetic data for Cl-INH 
were estimated in patients with acute myocardial in-
farction receiving high doses of this inhibitor. The 
obtained FCR value (0.011 h- 1) is lower than that 
previously found (0.025 h - I). Saturation of the normal 
steady-state kinetics of Cl-INH may explain this find-
ing. These data may help to design further clinical trials 
with this anti-inflammatory drug. 
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